TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (claimed): Preparation of the compound (I) involves: inoculating Actinomycetes strain MTCC 5597 onto a suitable agar based media; incubating the agar plate at 20-40 degrees C for a period of 3-10 days and obtaining mycelial growth; removing the mycelial growth from the agar plate and obtaining the agar medium containing the compound (I); optionally cutting the media into pieces; adding the media pieces into a suitable solvent; incubating the media dissolved in solvent at 23-30 degrees C for a period of 3-18 hours and extracting the compound (I); collecting the solvent part and concentrating the same; obtaining the concentrate containing the compound (I); and purifying the compound (I). In the method, the agar plates are preferably incubated at 28 degrees C for a period of 7 days. The media dissolved in solvent is preferably incubated at 28 degrees C for a period of 24 hours. The solvent part is concentrated using a rotary evaporator. The concentrate containing the compound (I) is optionally stored at 4-25 (preferably 4) degrees C before purification step. The purification is done by chromatography methods (preferably thin layer chromatography and column chromatography). The purification is done by crystallization methods such as single solvent recrystallization or multi solvent recrystallization. Preferred Compound: The compound is brominated. Preferred Components: The media is selected from yeast extract malt extract agar, glycerol asparagine agar, oatmeal agar, czapek's dox agar and tyrosine agar. The solvent is an organic solvent selected from methanol, chloroform, dichloromethane, diethyl ether, ethyl acetate and n-hexane.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition is formulated in various forms such as liquid, solid, powder and lozenges. ACTIVITY - Antibacterial; Virucide; Anti-HIV. The efficacy of 5-(4-bromobutyl)-N-(but-3-enyl)dodec-11-enamide (I) was evaluated for antibacterial activity against Mycobacterium tuberculosis H37Rv cell suspension using luciferase reporter phage (LRP) assay, and minimum inhibitory concentration (MIC) was determined. The compound (I) showed MIC of less than 1 mu g/ml.    MECHANISM OF ACTION - None given.    EXAMPLE - No suitable example given.